Zoe Clancy

Bristol-Myers Squibb (United States) — United States

Medicine · Health Sciences

5h-index356citations44works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(14), Health Systems, Economic Evaluations, Quality of Life(11), Rheumatoid Arthritis Research and Therapies(6), Pharmaceutical Economics and Policy(6), Economic and Financial Impacts of Cancer(6)

Publications44 total

Association between Spending in Oncology Care Model-Defined Episodes and Overall Survival in Multiple Myeloma Using 2012-2017 Medicare Data
Blood·2020
A real-world comparative analysis of pomalidomide (POM) and other antimyeloma treatments following lenalidomide (LEN) discontinuation among patients with multiple myeloma.
Journal of Clinical Oncology·2020· 1 cited
PCN104 TREATMENT PATTERNS AND HEALTH CARE COSTS IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)TREATMENT PATTERNS AND HEALTH CARE COSTS IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
Value in Health·2020
PCN118 TREATMENT PATTERNS AND HEALTH CARE COSTS IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
Value in Health·2020
Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis
Blood Advances·2019· 124 citedOpen Access
Assessing the Effect of Pomalidomide or Carfilzomib Treatment on Patient-Reported Outcomes Among Patients With Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2019
Examining Treatment Patterns, Patient Characteristics, and Outcomes Associated With Pomalidomide in Multiple Myeloma Following Lenalidomide Therapy
Clinical Lymphoma Myeloma & Leukemia·2019· 1 cited
Association Between Costs of Care in Oncology Care Model (OCM)-Defined Episodes and Overall Survival in Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2019
PF720 MEDICAL COSTS ASSOCIATED WITH RELAPSE AMONG PATIENTS WITH FOLLICULAR LYMPHOMA
HemaSphere·2019Open Access
PF496 TREATMENT PATTERNS AMONG PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA
HemaSphere·2019Open Access
Burden of CRAB Events By Relapse in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Stem Cell Transplant
Blood·2018
Real-world economic outcomes of early progression in newly diagnosed multiple myeloma (NDMM) patients (Pts).
Journal of Clinical Oncology·2018· 3 cited
Survival gains in multiple myeloma from 2003 to 2014.
Journal of Clinical Oncology·2018· 1 cited
Assessing Patient-Reported Outcomes and Work Productivity Along the Multiple Myeloma (MM) Patient Journey
Value in Health·2018
The Importance of Economic Trade-offs in Cancer Drug Pricing
Mayo Clinic Proceedings·2018· 4 citedOpen Access
Novel treatment (Tx) use and associated outcomes among African American patients (pts) with multiple myeloma (MM): A SEER-Medicare analysis.
Journal of Clinical Oncology·2018· 1 cited
Economic burden of early progression in newly-diagnosed multiple myeloma patients.
Journal of Clinical Oncology·2018· 3 cited
Drivers of phase-based costs in patients with multiple myeloma.
Journal of Clinical Oncology·2018· 2 cited
Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, And Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)
Value in Health·2018· 1 citedOpen Access
Using an Enhanced Electronic Heath Record to Analyze Treatment Patterns and Clinical Characteristics in Patients with Relapsed or Refractory Multiple Myeloma Receiving Pomalidomide
Blood·2017
page 1 of 3Next →

Frequent Co-authors

Ronda Copher(9), Zheng‐Yi Zhou(4), Jacqueline Pesa(4), T. Tencer(4), Andreas Kuznik(4), Kejal Parikh(3), Safiya Abouzaid(3), Shivani Pandya(3), Sulena Shrestha(3), Li Wang(3), Onur Baser(3), Sandra Virtue(2), Jason Haberman(2), Todd B. Parrish(2), Mark Beeman(2), Sikander Ailawadhi(2), Zhou Zhou(2), Wenxi Tang(2), Claudia Cheung(2), Jipan Xie(2)